An Exploratory, Cross-Over Study of the Safety of HP802-247 Applied to Open Wounds of Subjects With Dystrophic Epidermolysis Bullosa
Latest Information Update: 06 Nov 2021
At a glance
- Drugs HP 802247 (Primary)
- Indications Epidermolysis bullosa dystrophica
- Focus Therapeutic Use
- Sponsors Smith & Nephew Biotherapeutics
- 30 Sep 2014 New trial record